Investigation of the abuse liability of buspirone in alcohol-dependent patients

Griffith, John D.; Jasinski, Donald R.; Casten, George P.; McKinney, Gordon R.

doi:10.1016/0002-9343(86)90329-3

Cited by 79 publications

(14 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In marked contrast to diazepam. buspirone exhibits low abuse potential in alcohol-dependent patients [12], Buspirone has been shown to reduce alco hol intake in monkeys and rats induced to prefer ethanol to water [10,11 ]. In an unpub lished study using mice that selected alcohol over water, this preference was reversed af ter buspirone treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Buspirone also reduced alcohol in take in monkeys [10] and rats [11] that were induced to drink ethanol chronically. In a study with alcohol-dependent inpatients, buspirone, in contrast to diazepam, was sig nificantly differentiated from alcohol or sed atives on the appropriate Addiction Re search Center Inventory subscales [12]. The decreased alcohol consumption in three ani mal models, low abuse liability in alcoholdependent patients, and generally favorable safety profile suggest that buspirone may have therapeutic benefit in alcoholic pa tients.…”

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Buspirone in the Treatment of Alcoholic Patients

Bruno

1989

Psychopathology

133

View full text Add to dashboard Cite

Buspirone is a unique anxiolytic drug with established efficacy in the treatment of anxiety. In animals, buspirone has been shown to alter drinking preference from alcohol to water. The following study was conducted to evaluate the behavioral effects of buspirone in patients meeting the Diagnostic and Statistical Manual of Mental Disorders (3rd ed.; DSM-III) criteria of alcohol abuse. These patients were motivated to reduce or stop drinking, though none were abstinent at baseline. Buspirone was compared with placebo in a double-blind, 8-week trial in 50 outpatients with mild to moderate alcohol abuse. Patients were assessed at baseline and at end point using the following psychometric and alcohol behavior measures: Drinking Behavior Interview (DBI), Alcohol Craving Scale, the Hamilton Anxiety (HAM-A) Rating Scale, the Hamilton Depression (HAM-D) Rating Scale, and the Physician Questionnaire. Dosage was initiated at 5 mg buspirone 3 times a day (15 mg/day), with a flexible regimen to a maximum of 30 mg/day. The mean daily dose was 20.5 mg buspirone, which is comparable to the anxiolytic dose. Efficacy measures were available for 45 patients (24 buspirone, 21 placebo). The treatment discontinuation rate was markedly lower (p = 0.002) on buspirone; 12 placebo patients and 2 buspirone patients discontinued due to lack of effect (p = 0.001). No patients discontinued due to adverse effect. Buspirone reduced alcohol craving by 40% (p = 0.001), in association with reduced HAM-A and HAM-D scores (p = 0.006) and improved the physician’s assessment of global psychopathology. Buspirone treatment was also associated with a 57% decrease in DBI scores; statistical comparison of the DBI data with placebo was precluded by the high discontinuation rate in the placebo group. While these results should be interpreted with caution due to the limited sample size and high placebo discontinuation rate, the findings suggest that further evaluation of buspirone in the management of alcoholism, especially abstinent alcoholics, is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

Buspirone in the Treatment of Alcoholic Patients

Bruno

1989

Psychopathology

133

View full text Add to dashboard Cite

show abstract

“…It is a nonopioid alternative for the management of withdrawal. It is not sedating, has no abuse potential, 24,25 has no withdrawal symptoms, 26 has a safe side effects profile, 27,28 spares patients undesirable effects on psychomotor function, 29,30 and does not potentiate the effects of central nervous system depressants. 31 …”

Section: Discussionmentioning

confidence: 99%

Efficacy of Buspirone in the Treatment of Opioid Withdrawal

Buydens‐Branchey

Branchey

Reel-Brander

2005

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

In an attempt to develop a new opiate detoxification approach, the authors assessed the efficacy of buspirone in the treatment of acute heroin withdrawal. Buspirone, a drug interacting with the serotonergic system, was selected because there is evidence that a decrease in serotonergic neurotransmission may be involved in opiate withdrawal symptoms. Twenty-nine hospitalized heroin addicts were randomized to 4 groups: (1) placebo; (2) methadone; (3) buspirone 30 mg daily; (4) buspirone 45 mg daily. The double-blind trial started in all patients with a 5-day methadone stabilization period ending with a 30-mg dose. This was followed from days 6 through 12 by placebo in group 1 and by a methadone taper in group 2. Because of its delayed action, buspirone was started on day 1 in groups 3 and 4 and was continued, after methadone discontinuation, through day 12. On day 13, drugs and placebo were discontinued and patients were observed through day 14. Withdrawal symptoms were assessed with the "Subjective Opiate Withdrawal Scale" (SOWS) and the "Objective Opiate Withdrawal Scale" (OOWS). The SOWS and OOWS scores were significantly higher in the placebo group than in the methadone, buspirone 30 mg, and buspirone 45 mg groups. There were no significant differences in SOWS or OOWS scores when the methadone group was compared with each of the two buspirone groups or when the two buspirone groups were compared with one another. In conclusion, buspirone, a nonopiate drug with no abuse potential, a safe side effect profile and no withdrawal symptoms, at doses of 30 and 45 mg, was as effective as a methadone taper in alleviating the withdrawal symptoms of heroin addicts stabilized for 5 days with, and then withdrawn from, methadone. The use of buspirone could be particularly helpful in outpatient settings where the duration of the methadone taper recommended for detoxification can be lengthy.

show abstract

“…Как показывают предшествующие исследования, эти дозы безопасны и хорошо переносятся [15]. Коррек-ция абстинентной тревоги под действием буспирона мо-жет также способствовать терапии алкогольной и табач-ной зависимости [16][17][18].…”

Section: применение буспирона для лечения синдрома зависимостиunclassified

The use of buspirone in clinical practice

2015

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Investigation of the abuse liability of buspirone in alcohol-dependent patients

Cited by 79 publications

References 6 publications

Buspirone in the Treatment of Alcoholic Patients

Buspirone in the Treatment of Alcoholic Patients

Efficacy of Buspirone in the Treatment of Opioid Withdrawal

The use of buspirone in clinical practice

Contact Info

Product

Resources

About